Friday, March 19, 2021 Daily Archives

Fujifilm selects NC for 160,000 L mammalian plant

Infrastructure, state incentives, and proximity to an existing facility have driven CDMO Fujifilm Diosynth Biotechnologies to select Holly Springs, North Carolina as the site of its ¥200 billion biologics plant. In January, Fujifilm Corporation announced plans to invest ¥200 billion (then $2 billion, now $1.8 billion) to build a biologics facility in the US run by its contract development and manufacturing organization (CDMO) business Fujifilm Diosynth Biotechnologies (FDB). Details, including the planned mammalian cell culture capacity of 160,000 L (made…

Catalent increases capacity in Italy for J&J’s COVID vaccine

Catalent will add a high-speed vial-filling line to increase its manufacturing capacity for J&J’s single-shot COVID-19 vaccine. The expanded partnership will see contract development manufacturing organization (CDMO) Catalent add an additional high-speed vial-filling line at its site in Anagni, Italy. The line is set to be operational by the fourth quarter of 2021 and support the making of Johnson & Johnson’s (J&J) COVID-19 vaccine throughout 2022. The CDMO said the increase in its manufacturing capacity at the 300,000 square-foot Italian…

COVID catalyst: MilliporeSigma expedites $30m French expansion

MilliporeSigma has accelerated plans to add a single-use assembly production unit at its site in Molsheim, France on the back of COVID-19 demand. The $30 million injection at the site, just west of Strasbourg, will add 18,300 square feet of cleanroom space to produce MilliporeSigma’s Mobius single-use assemblies for use in the production of both COVID-19 vaccines and other therapies. The expansion will generate more than 350 jobs. The facility will become the first European site to make the single-use…